Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Aspirin-a-day advice unheeded by those who need it

15.11.2005


A daily dose of aspirin is an inexpensive, proven strategy for reducing the likelihood of heart disease among those most at risk for such disorders, yet a new study from the Stanford University School of Medicine shows that aspirin therapy is being used by fewer than one-third of the U.S. outpatients who would benefit from it.



Instead, the research found, many doctors are opting to prescribe the more expensive, heavily marketed statin drugs, which are no more effective than aspirin in preventing heart disease.

"What really concerns us is the degree of aspirin underutilization among patients who have already had a heart attack or a stroke because this is the group for which there is conclusive clinical evidence that aspirin reduces the risk for cardiovascular disease," said Jun Ma, MD, PhD, research associate at the Stanford Prevention Research Center and senior author of the study that appears in the November issue of the Public Library of Science-Medicine.


Of those with the highest risk for cardiovascular disease, the study showed that only 33 percent of their outpatient visits were associated with aspirin therapy in 2003. That’s an increase from the 1993 rate of 22 percent, but Ma said the gain is minimal considering the abundant proof of aspirin’s benefits for such patients.

And although aspirin use remains low, the study found that U.S. physicians are increasingly prioritizing a class of drugs known as statins as the primary drug strategy for preventing heart disease. Statins, while as effective as aspirin in preventing heart attacks, cost substantially more. The researchers speculate that the heavy marketing of statins in the United States is spurring patients and doctors toward these newer - although not necessarily better - medications.

"Our concern is that physicians are failing to use the full range of strategies available to reduce patients’ risk of heart disease and stroke," said Randall Stafford, MD, PhD, associate professor of medicine at the Stanford Prevention Research Center and the first author of the study.

Cardiovascular disease remains the leading cause of death in the United States for both men and women. The American Heart Association estimates that the various types of cardiovascular disease, including heart attack and stroke, affect more than 70 million Americans.

Aspirin therapy is one way for patients diagnosed with a significant risk for heart disease to lower that risk. Aspirin reduces the clotting action of the blood’s platelets, thereby lowering the risk of heart attack, stroke and other diseases that can occur when the blood vessels are blocked by clots. In several clinical trials, daily doses of between 75 and 325 milligrams of aspirin cut the risk of cardiovascular events by 15 to 40 percent. However, aspirin can cause gastrointestinal bleeding in up to 4.5 percent of patients; physicians and patients must weigh that risk against aspirin’s benefits before deciding whether to use it.

For several years, clinical guidelines have recommended aspirin therapy for patients with a significant risk of heart disease. Ma and Stafford said their study is the first to examine how aspirin use varies among U.S. outpatients according to their heart-disease risk.

The researchers used two national databases that tracked outpatient visits to hospitals and physician offices between 1993 and 2003, and then assessed the reported use of aspirin therapy associated with those visits. Patients were categorized according to their risk of cardiovascular disease. High-risk patients were those who had been diagnosed with heart disease or had experienced a heart attack or stroke. Intermediate-risk patients were divided into two groups: one for those who had diabetes and additional risk factors for heart disease (such as high blood pressure, high cholesterol and smoking); and the other for non-diabetic adults with at least two risk factors for heart disease. All other patients were placed in the low-risk category.

While less than a third of the high-risk patient visits were associated with aspirin therapy, the 2003 rates were even lower for those in the intermediate groups: 12 percent of the diabetic group and 16 percent for the non-diabetics.

Ma and Stafford acknowledged that measuring aspirin usage is difficult because doctors don’t always document the over-the-counter medications their patients take. However, based on previous studies that found low rates of aspirin use, the researchers said they don’t believe such under-reporting would account for the huge gap between the clinical recommendations and what they found in the new study.

One finding that intrigued the researchers is the growing popularity of statins, which help reduce the amount of LDL or "bad" cholesterol in the blood. Statins and aspirin have similar overall rates of effectiveness in reducing cardiovascular risk, but they vary significantly in cost. A daily dose of the most frequently prescribed statin medication costs around $2 while a daily dose of aspirin costs mere pennies.

Susan Ipaktchian | EurekAlert!
Further information:
http://www.stanford.edu
http://mednews.stanford.edu

More articles from Health and Medicine:

nachricht 'Living bandages': NUST MISIS scientists develop biocompatible anti-burn nanofibers
16.02.2018 | National University of Science and Technology MISIS

nachricht New process allows tailor-made malaria research
16.02.2018 | Eberhard Karls Universität Tübingen

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: In best circles: First integrated circuit from self-assembled polymer

For the first time, a team of researchers at the Max-Planck Institute (MPI) for Polymer Research in Mainz, Germany, has succeeded in making an integrated circuit (IC) from just a monolayer of a semiconducting polymer via a bottom-up, self-assembly approach.

In the self-assembly process, the semiconducting polymer arranges itself into an ordered monolayer in a transistor. The transistors are binary switches used...

Im Focus: Demonstration of a single molecule piezoelectric effect

Breakthrough provides a new concept of the design of molecular motors, sensors and electricity generators at nanoscale

Researchers from the Institute of Organic Chemistry and Biochemistry of the CAS (IOCB Prague), Institute of Physics of the CAS (IP CAS) and Palacký University...

Im Focus: Hybrid optics bring color imaging using ultrathin metalenses into focus

For photographers and scientists, lenses are lifesavers. They reflect and refract light, making possible the imaging systems that drive discovery through the microscope and preserve history through cameras.

But today's glass-based lenses are bulky and resist miniaturization. Next-generation technologies, such as ultrathin cameras or tiny microscopes, require...

Im Focus: Stem cell divisions in the adult brain seen for the first time

Scientists from the University of Zurich have succeeded for the first time in tracking individual stem cells and their neuronal progeny over months within the intact adult brain. This study sheds light on how new neurons are produced throughout life.

The generation of new nerve cells was once thought to taper off at the end of embryonic development. However, recent research has shown that the adult brain...

Im Focus: Interference as a new method for cooling quantum devices

Theoretical physicists propose to use negative interference to control heat flow in quantum devices. Study published in Physical Review Letters

Quantum computer parts are sensitive and need to be cooled to very low temperatures. Their tiny size makes them particularly susceptible to a temperature...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

2nd International Conference on High Temperature Shape Memory Alloys (HTSMAs)

15.02.2018 | Event News

Aachen DC Grid Summit 2018

13.02.2018 | Event News

How Global Climate Policy Can Learn from the Energy Transition

12.02.2018 | Event News

 
Latest News

Contacting the molecular world through graphene nanoribbons

19.02.2018 | Materials Sciences

When Proteins Shake Hands

19.02.2018 | Materials Sciences

Cells communicate in a dynamic code

19.02.2018 | Life Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>